Brought to you by 
Evelo partners with Univ. of Chicago, options gut microbe immunotherapy; therapy licensed
10 Nov 2021
Executive Summary
The University of Chicago granted Evelo Therapeutics an option to exclusively license global rights to a microbiome-based immunotherapy developed by the university's Thomas Gajewski, MD, PhD.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Evelo partners with Univ. of Chicago, options gut microbe immunotherapy; therapy licensed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice